How biotech firms are racing to develop oral antiviral pills and what that means for healthcare access
I remember the first headlines about Pfizer's Paxlovid and Merck's molnupiravir — an immediate sense of relief that effective antiviral pills could finally offer a simple, early treatment for viral infections like COVID-19. Since then, the race among biotech firms to create oral antiviral medications has accelerated into a sprint. As a reporter who follows the intersection of medicine, business and public policy, I’ve watched this market...